AlphAIalphai — Financial news for AI agents
investing.comAUG 74 min read$DOCS

Why is Doximity stock skyrocketing 66% today?

Doximity shares rose about 66% in pre-open after the company reported fiscal Q1 2027 results. Revenue was $156.6M, above the $151.7M consensus, and adjusted EBITDA was $75M with a 48% margin. Doximity raised full-year revenue guidance by $6M to $671M-$681M, citing AI product traction, including Doximity Ask.

Original reporting
investing.com
Published Aug 7, 2026, 8:32 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 8:52 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$DOCS
Bullish
medium confidence
Mentioned
$DOCS
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$DOCSBullishMed
01

Why it matters

A clean revenue beat and a raised full-year revenue range are the core repricing drivers, reinforced by management commentary that AI engagement is gaining traction.

02

Market read

Traders can treat this as a guidance-reset catalyst for DOCS, with AI product traction used to justify durable demand.

03

What to watch

The article notes the stock started near a 52-week low, so short-covering and mean-reversion dynamics may have amplified the move beyond fundamentals.

Relevance 8/10Novelty 7/10Timing: pre-open today after prior-evening fiscal Q1 2027 results

Background

DOCS had been pressured after a prior-quarter earnings miss and guidance cut, leaving the stock near its 52-week low before this report.

Company-level read

Ticker impact

$DOCSBullishMedium confidence
Context

Doximity surged pre-open after reporting fiscal Q1 2027 results that beat revenue expectations and raised full-year guidance.

Expected impact

Likely elevated volatility and momentum early as traders reprice DOCS on the raised guidance and AI traction narrative.

Evidence & confidence

The article cites specific upside catalysts: revenue beat ($156.6M vs $151.7M), raised revenue guidance ($671M-$681M), and AI product momentum (NOHARM ranking, AI Search gaining traction).

Market effects

Sector

Supports the digital health and health-tech narrative that AI features can shift earnings expectations from margin pressure to growth.

Regional

No specific regional spillover beyond a mild S&P 500/NASDAQ uptick.

Global

Limited direct global linkage; mainly a US-listed growth/AI adoption signal.

Counterpoint

What could challenge this read

The EPS miss (by $0.01) and reliance on early AI traction could mean the guidance raise is optimistic and may face skepticism if follow-through is weaker.

Key entities

  • company
    Doximity

    DOCS surged 66% pre-open after fiscal Q1 2027 results beat revenue expectations and management lifted full-year targets, citing AI product traction.

  • person
    Jeff Tangney

    CEO who highlighted Doximity Ask’s NOHARM benchmark ranking and AI Search momentum for pharmaceutical clients.

Read at source← All news

Related articles

AUG 7
$DOCSHighAI 9/10

A Lesser-Known Stock Climbed More Than 100% In a Day After AI Surprise. Here’s Why.

Doximity (DXRX) shares jumped after the company reported fiscal Q1 2027 results and said its new AI search product is generating strong unit economics. CEO Jeffrey Tangney said revenue is over 10 times per search versus cost. Q1 revenue was $156.6M and adjusted EBITDA $74.8M. Full-year revenue guidance raised to $671M-$681M; short interest was about 17%, contributing to a short squeeze.

ibtimes.com6 min
AUG 7
$DOCSMedAI 8/10

Why Doximity Stock Is Up 80%

Doximity (NYSE:DOCS) shares jumped about 80% after CEO Jeffrey Tangney said its new AI search tool generates over 10 times more revenue per search than it costs. The company reported Q revenue up 7% to $156.6M and adjusted EBITDA of $74.8M, and raised full-year revenue guidance to $671M-$681M. FactSet said 17% of tradable shares were short before the report.

yahoo.com6 min
AUG 7
$DOCSHighAI 9/10

Doximity Raises Full-Year Guidance as AI Scribe Surges Tenfold, Clinical AI Tops Safety Study

Doximity (NYSE: DOCS) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Revenue was $156.6M, up 7% and above consensus $151.7M; adjusted EBITDA was $74.8M. The company raised full-year revenue guidance to $671M-$681M and said Doximity Scribe active users rose tenfold and its Ask ranked first in the NOHARM clinical AI safety study. DOCS shares jumped in premarket.

techtimes.com6 min
AUG 7
$DOCSMed

Doximity's stock skyrockets 50% on medical AI excitement. Can the rally last?

Doximity (DOCS) shares rose as much as 94% and were up about 50% after its earnings call, despite mixed results. Management highlighted medical AI progress, including a “winning model” with 4.8% error vs 13.6% for Anthropic’s Fable 5, and said it earns over 10x search revenue vs cost. FY revenue guidance was raised to $671M-$681M from $664M-$676M; adjusted EPS was 29 cents.

morningstar.com6 min
AUG 7
$DOCSHighAI 9/10

Doximity Soars After Q1 Revenue Tops Guidance; Raises FY2027 View

Doximity (DOCS) reported Q1 FY2027 revenue of $156.62M, up 7% and above its prior guidance range of $151M to $152M. Net income fell to $24.32M ($0.13/share) from $53.32M ($0.27). For Q2, it expects revenue of $170M to $171M and adjusted EBITDA of $80.5M to $81.5M. FY2027 revenue guidance was raised to $671M to $681M.

rttnews.com4 min